EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Precision Antibody Therapy in Gastric and Gastroesophageal Cancer: Targeting FGFR2b, CLDN18.2, and VEGFR2

Vivian Chetachi Eziefula Njoku iD, Yein Lee iD, Joytish Ramesh iD, Peter Kubatka iD, Dietrich Büsselberg iD

Cells · 26.10.2025 · 14 (21) · 1672

DOI: 10.3390/cells14211672 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 26.10.2025. Verfasst von Vivian Chetachi Eziefula Njoku und 4 weiteren Autor:innen. Beteiligte Einrichtung: Weill Cornell Medicine-Qatar, Doha P.O. Box 24144, Qatar. Hauptthemen laut MEDLINE: Stomach Neoplasms, Receptor, Fibroblast Growth Factor, Type 2, Precision Medicine, Esophageal Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Qatar National Research Fund, National Priorities Research Program, Qatar Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gastric and gastroesophageal junction (G/GEJ) adenocarcinomas remain among the most aggressive and lethal malignancies globally. Most patients are diagnosed at advanced stages and respond poorly to conventional chemotherapy, highlighting the urgent demand for more effective, novel treatment strategies such as monoclonal antibody therapies targeting drivers of tumor progression. This review examines the mechanisms, safety profiles, and clinical trial outcomes of three targeted agents—bemarituzumab, zolbetuximab, and ramucirumab—which inhibit tumor growth through the FGFR2b, CLDN18.2, and VEGFR2 pathways, respectively. We also compare traditional versus adaptive clinical trial designs, explore emerging challenges such as therapeutic resistance and treatment-related toxicities, and consider implications for personalized medicine. Collectively, these agents represent a paradigm shift from empiric chemotherapy toward biomarker-driven immunotherapy, with the potential to significantly improve survival and quality of life in patients with advanced G/GEJ cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsReceptor, Fibroblast Growth Factor, Type 2Precision MedicineEsophageal NeoplasmsClaudinsVascular Endothelial Growth Factor Receptor-2HumansEsophagogastric JunctionRamucirumabAntibodies, MonoclonalAnimals

Stichwörter der Autor:innen

bemarituzumabgastric cancergastroesophageal junction cancermonoclonal antibodiesramucirumabtargeted therapyzolbetuximab

Substanzen

Receptor, Fibroblast Growth Factor, Type 2ClaudinsVascular Endothelial Growth Factor Receptor-2CLDN18 protein, humanFGFR2 protein, humanRamucirumabAntibodies, MonoclonalKDR protein, human

Autor:innen und Institutionen

  • Weill Cornell Medicine-Qatar, Doha P.O. Box 24144, Qatar.
  • Centre of Experimental and Clinical Regenerative Medicine, Small Animal Clinic, University of Veterinary Medicine and Pharmacy, 041 81 Kosice, Slovakia.

ORCID-Profile: Vivian Chetachi Eziefula Njoku, Yein Lee, Joytish Ramesh, Peter Kubatka, Dietrich Büsselberg

Förderung

  • Qatar National Research Fund
  • National Priorities Research Program
  • Qatar Foundation

Zitieren

APA

Njoku, V. C. E., Lee, Y., Ramesh, J., Kubatka, P., & Büsselberg, D. (2025). Precision Antibody Therapy in Gastric and Gastroesophageal Cancer: Targeting FGFR2b, CLDN18.2, and VEGFR2. Cells, 14(21), 1672. https://doi.org/10.3390/cells14211672

Vancouver

Njoku VCE, Lee Y, Ramesh J, Kubatka P, Büsselberg D. Precision Antibody Therapy in Gastric and Gastroesophageal Cancer: Targeting FGFR2b, CLDN18.2, and VEGFR2. Cells. 2025;14(21):1672. doi:10.3390/cells14211672

BibTeX
@article{Njoku2025,
  author = {Njoku, Vivian Chetachi Eziefula and Lee, Yein and Ramesh, Joytish and Kubatka, Peter and Büsselberg, Dietrich},
  title = {Precision Antibody Therapy in Gastric and Gastroesophageal Cancer: Targeting FGFR2b, CLDN18.2, and VEGFR2},
  journal = {Cells},
  year = {2025},
  volume = {14},
  number = {21},
  pages = {1672},
  doi = {10.3390/cells14211672}
}
Kostenlos starten →